Pulmonary veno-occlusive disease

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 189-200

  Montani, D ^a   Price, L C ^a   Dorfmuller, P ^a   Achouh, L ^a   Jais X ^a   Yaici A ^a   Sitbon, O ^a   Musset, D ^a   Simonneau, G ^a   Humbert, M ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Alveolar haemorrhage; BMPR2; Computed tomography; Diffusing capacity of the lung for carbon monoxide; Pulmonary arterial hypertension; Pulmonary veno occlusive disease

Indexed keywords

ADENOSINE; AMINOREX; ANTICOAGULANT AGENT; AZATHIOPRINE; BLEOMYCIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; CARMUSTINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENFLURAMINE; GLUCOCORTICOID; HEMOSIDERIN; ILOPROST; IMMUNOSUPPRESSIVE AGENT; MITOMYCIN; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PYRROLIZIDINE ALKALOID; SILDENAFIL; VASODILATOR AGENT; WARFARIN;

ANTICOAGULATION; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; BRONCHOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; GENE MUTATION; GENETIC RISK; HEART MURMUR; HEART RIGHT VENTRICLE FAILURE; HEMOPTYSIS; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; IDIOPATHIC DISEASE; IMAGE QUALITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG FUNCTION TEST; LUNG GRANULOMATOSIS; LUNG HEMODYNAMICS; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPH NODE HYPERPLASIA; MACROPHAGE; MONOTHERAPY; MORTALITY; NON INVASIVE PROCEDURE; NONHUMAN; OCCULT BLOOD; OXYGEN SATURATION; OXYGEN THERAPY; OXYGENATION; PATHOGENESIS; PLEURA EFFUSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VEIN OBSTRUCTION; PULMONARY VENO-OCCLUSIVE DISEASE; PULSE OXIMETRY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SCLERODERMA; SEX RATIO; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; VASCULAR PATENCY; WALKING;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; PROGNOSIS; PULMONARY VENO-OCCLUSIVE DISEASE; PULMONARY WEDGE PRESSURE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58849085018     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00090608     Document Type: Review

References (93)

1. Rubin L. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
3. Höra J. Zur histologie der klinischen "primaren pulmonalsklerose". [On the histology of clinical primary pulmonary sclerosis]. Frankf Z Pathol 1934; 47: 100-118.
4. Montani D, Achouh L, Dorfmuller P, et al. Pulmonary venoocclusive disease: Clinical, functional, radiologic, hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87: 220-233.
5. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25S-32S.
6. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850-857.
7. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671-1679.
8. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
9. Rabiller A, Jais X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27: 108-113.
10. Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183: 65-70.
11. Rambihar VS, Fallen EL, Cairns JA. Pulmonary venoocclusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings. Can Med Assoc J 1979; 120: 1519-1522.
12. Humbert M, Nunes H, Sitbon O, Parent F, Hervé P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-475.
13. Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902.
14. Johnson SR, Patsios D, Hwang DM, Granton JT. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006; 33: 2347-2350.
15. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533-547.
16. Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171: 1321-1324.
17. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
18. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
19. Escamilla R, Hermant C, Berjaud J, Mazerolles C, Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995; 8: 1982-1984.
20. Hourseau M, Capron F, Nunes H, Godmer P, Martin A, Kambouchner M. Maladie veino-occlusive pulmonaire et infection par le VIH. [Pulmonary veno-occlusive disease in a patient with HIV infection. A case report with autopsy findings]. Ann Pathol 2002; 22: 472-475.
21. Ruchelli ED, Nojadera G, Rutstein RM, Rudy B. Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994; 118: 664-666.
22. Williams LM, Fussell S, Veith RW, Nelson S, Mason CM. Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 1996; 109: 1388-1391.
23. Kuga T, Kohda K, Hirayama Y, et al. Pulmonary venoocclusive disease accompanied by microangiopathic hemolytic anaemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol 1996; 64: 143-150.
24. Troussard X, Bernaudin JF, Cordonnier C, et al. Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 1984; 39: 956-957.
25. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 1996; 18: 755-760.
26. Seguchi M, Hirabayashi N, Fujii Y, et al. Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000; 69: 177-179.
27. Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989; 47: 989-992.
28. Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant 2008; 41: 677-686.
29. Zhang L, Visscher D, Rihal C, Aubry MC. Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease. Rheumatol Int 2007; 27: 1163-1165.
30. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, hemodynamics and prognosis. Thorax 2006; 61: 68-74.
31. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161: 216-223.
32. Hamada K, Teramoto S, Narita N, Yamada E, Teramoto K, Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15: 421-423.
33. Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982; 13: 911-915.
34. Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977; 32: 763-766.
35. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003; 167: 889-894.
36. Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006; 27: 212-213.
37. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-132.
38. Human Genome Variation Society. Nomenclature for the description of sequence variations.www.hgvs.org/mutnomen Last accessed: September 2008. Last updated: October 2007.
39. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
40. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
41. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981; 283: 881-883.
42. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27: 160-171.
43. Tandon BN, Tandon HD, Tandon RK, Narndranathan M, Joshi YK. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2: 271-272.
44. Joselson R, Warnock M. Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983; 14: 88-91.
45. Knight BK, Rose AG. Pulmonary veno-occlusive disease after chemotherapy. Thorax 1985; 40: 874-875.
46. Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D. Pulmonary veno-occlusive disease and Hodgkin's lymphoma. Eur Respir J 1993; 6: 596-598.
47. Waldhorn RE, Tsou E, Smith FP, Kerwin DM. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anaemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984; 12: 394-396.
48. Trobaugh-Lotrario AD, Greffe B, Deterding R, Deutsch G, Quinones R. Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 2003; 25: 405-409.
49. Wright JL, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Am J Respir Cell Mol Biol 2004; 31: 501-509.
50. Wright JL, Tai H, Churg A. Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. J Appl Physiol 2006; 100: 672-678.
51. Di Biase L, Fahmy TS, Wazni OM, et al. Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: clinical implications after long-term follow-up. J Am Coll Cardiol 2006; 48: 2493-2499.
52. Weed HG. Pulmonary "capillary" wedge pressure not the pressure in the pulmonary capillaries. Chest 1991; 100: 1138-1140.
53. Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC. Pulmonary capillary pressure and filtration coefficient in the isolated perfused lung. Am J Physiol 1967; 213: 910-914.
54. Grimbert FA. Effective pulmonary capillary pressure. Eur Respir J 1988; 1: 297-301.
55. Cope DK, Allison RC, Parmentier JL, Miller JN, Taylor AE. Measurement of effective pulmonary capillary pressure using the pressure profile after pulmonary artery occlusion. Crit Care Med 1986; 14: 16-22.
56. Fesler P, Pagnamenta A, Vachiery JL, et al. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 2003; 21: 31-36.
57. Souza R, Amato MB, Demarzo SE, et al. Pulmonary capillary pressure in pulmonary hypertension. Crit Care 2005; 9: R132-R138.
58. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
59. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
60. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary oedema and death after prostacyclin infusion in a patient with pulmonary venoocclusive disease. Chest 1998; 113: 237-240.
61. Elliott CG, Colby TV, Hill T, Crapo RO. Pulmonary venoocclusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. Respiration 1988; 53: 262-266.
62. Wahidi MM, Rocha AT, Hollingsworth JW, Govert JA, Feller-Kopman D, Ernst A. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy. A survey of pulmonologists and review of the literature. Respiration 2005; 72: 285-295.
63. Matthews AW, Buchanan R. A case of pulmonary venoocclusive disease and a new bronchoscopic sign. Respir Med 1990; 84: 503-505.
64. Ohmichi M, Tagaki S, Nomura N, Tsunematsu K, Suzuki A. Endobronchial changes in chronic pulmonary venous hypertension. Chest 1988; 94: 1127-1132.
65. Swensen SJ, Tashjian JH, Myers JL, et al. Pulmonary venoocclusive disease: CT findings in eight patients. AJR Am J Roentgenol 1996; 167: 937-940.
66. Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974; 364: 69-79.
67. Chazova I, Robbins I, Loyd J, et al. Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis. Eur Respir J 2000; 15: 116-122.
68. Sanderson JE, Spiro SG, Hendry AT, Turner-Warwick M. A case of pulmonary veno-occlusive disease responding to treatment with azathioprine. Thorax 1977; 32: 140-148.
69. Gilroy RJ Jr, Teague MW, Loyd JE. Pulmonary venoocclusive disease. Fatal progression of pulmonary hypertension despite steroid-induced remission of interstitial pneumonitis. Am Rev Respir Dis 1991; 143: 1130-1133.
70. Jais X, Launay D, Yaiic A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
71. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
72. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
73. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-277.
74. Okumura H, Nagaya N, Kyotani S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002; 122: 1096-1098.
75. Resten A, Maitre S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002; 222: 782-788.
76. Davis LL, deBoisblanc BP, Glynn CE, Ramirez C, Summer WR. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995; 108: 1754-1756.
77. Barreto AC, Franchi SM, Castro CR, Lopes AA. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res 2005; 38: 185-195.
78. Creagh-Brown BC, Nicholson AG, Showkathali R, Gibbs JS, Howard LS. Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax 2008; 63: 933-934.
79. Barboza CE, Jardim CV, Hovnanian AL, Dias BA, Souza R. Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. J Bras Pneumol 2008; 34: 749-752.
80. Shackelford GD, Sacks EJ, Mullins JD, McAlister WH. Pulmonary venoocclusive disease: case report and review of the literature. AJR Am J Roentgenol 1977; 128: 643-648.
81. Hoeper MM, Eschenbruch C, Zink-Wohlfart C, et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med 1999; 93: 62-64.
82. Kuroda T, Hirota H, Masaki M, et al. Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease. Heart Lung Circ 2006; 15: 139-142.
83. 2 on calcium and magnesium fluxes and tension development in canine intralobar pulmonary arteries and veins. J Pharmacol Exp Ther 1981; 219: 326-337.
84. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
85. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
86. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 2002; 45: 115-128.
87. Cassart M, Gevenois PA, Kramer M, et al. Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation. AJR Am J Roentgenol 1993; 160: 759-760.
88. Izbicki G, Shitrit D, Schechtman I, et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant 2005; 24: 635-637.
89. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report 2001. J Heart Lung Transplant 2001; 20: 805-815.
90. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008; 371: 744-751.
91. Levine SM, Gibbons WJ, Bryan CL, et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990; 98: 1107-1115.
92. Pielsticker EJ, Martinez FJ, Rubenfire M. Lung and heartlung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001; 20: 1297-1304.
93. Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002; 73: 209-217.